Glaukos (NYSE:GKOS) Hits New 1-Year High on Better-Than-Expected Earnings

Glaukos Corporation (NYSE:GKOS) shares hit a new 52-week high during mid-day trading on Thursday following a better than expected earnings announcement. The stock traded as high as $229.27 and last traded at $232.6050, with a volume of 941,122 shares changing hands. The stock had previously closed at $181.43.

The medical instruments supplier reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. The business had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. The firm’s revenue was up 58.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.16) EPS.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record growth and profitability: Third-quarter revenue rose 58% year over year to approximately $211 million, well above the $168 million analyst consensus. Glaukos reported adjusted EPS of $0.47 versus expectations for a $0.10 loss, while GAAP results showed $2 million in net income, or $0.03 per diluted share, compared with a loss in the prior-year quarter. Glaukos Q3 earnings and revenue report
• Positive Sentiment: Higher sales outlook: Management raised 2026 revenue guidance to $775 million-$785 million from $680 million-$700 million and introduced a preliminary 2027 sales target of approximately $1 billion. The outlook reflects continued momentum in the company’s glaucoma and corneal-health franchises, including iDose TR and Epioxa. Glaukos strong Q3 results and higher sales outlook
• Positive Sentiment: Analysts raised targets and ratings: Needham lifted its target to $251, BTIG raised its target to $234, and Stifel increased its target to $225; all three firms now rate GKOS “Buy.” The new targets imply meaningful upside from the stock’s recent trading level. Needham analyst ratings
• Positive Sentiment: Healthy financial position: Glaukos generated $14.8 million in operating cash flow and ended the quarter with $162.3 million in cash, supporting continued investment in product development and commercialization.
• Neutral Sentiment: The earnings call and financial releases will be closely watched for additional details on adoption, reimbursement, and the pace at which iDose TR and Epioxa can support the ambitious 2027 sales target. Glaukos Q3 earnings call transcript
• Negative Sentiment: Quiver data shows 32 open-market insider sales and no purchases over the past six months, including selling by senior executives. While such transactions may reflect compensation or diversification, the pattern is a potential secondary concern for investors.

Analyst Ratings Changes

GKOS has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $240.00 price target (up from $195.00) on shares of Glaukos in a report on Thursday. BTIG Research upped their price target on Glaukos from $205.00 to $234.00 and gave the company a “buy” rating in a research report on Thursday. HC Wainwright upped their price target on shares of Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Needham & Company LLC lifted their price objective on Glaukos from $201.00 to $251.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Citigroup reissued a “buy” rating on shares of Glaukos in a research note on Thursday. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $201.57.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 60,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares of the company’s stock, valued at $13,046,967.12. The trade was a 45.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Alex Thurman sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at approximately $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 83,025 shares of company stock valued at $14,950,006. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Glaukos

A number of institutional investors have recently modified their holdings of GKOS. Sumitomo Mitsui Trust Group Inc. bought a new stake in Glaukos during the 3rd quarter valued at $1,248,000. Vise Technologies Inc. acquired a new position in Glaukos during the third quarter worth $668,000. State of Wyoming lifted its stake in shares of Glaukos by 6.8% in the third quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier’s stock valued at $169,000 after buying an additional 66 shares in the last quarter. Choreo LLC lifted its stake in shares of Glaukos by 4.0% in the third quarter. Choreo LLC now owns 3,546 shares of the medical instruments supplier’s stock valued at $582,000 after buying an additional 136 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC grew its holdings in shares of Glaukos by 35.6% during the third quarter. Fifth Third Wealth Advisors LLC now owns 2,172 shares of the medical instruments supplier’s stock valued at $357,000 after buying an additional 570 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Price Performance

The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The business’s fifty day moving average price is $171.24 and its 200-day moving average price is $139.87. The stock has a market capitalization of $13.58 billion, a price-to-earnings ratio of -70.02 and a beta of 0.69.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.